New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.
about
Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial FibrillationTrends in the prevalence and management of pre-stroke atrial fibrillation, the South London Stroke Register, 1995-2014.Outcome of intracerebral hemorrhage associated with different oral anticoagulants.Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarinEconomic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.Predictors of Thromboembolic Events in Patients with Ventricular Assist Device.Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant typeSupervised patient self-testing of warfarin therapy using an online system.New oral anticoagulants: are coagulation units still required?Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACsAntithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves.Arterial thromboembolism: risks, realities and a rational first-line approach.Anticoagulants in atrial fibrillation patients with chronic kidney disease.Target specific oral anticoagulants in the management of thromboembolic disease in the elderly.Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.Investigational anticoagulants for hematological conditions: a new generation of therapies.Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting.Risk of long-term anticoagulation under sustained severe arterial hypertension: A translational study comparing warfarin and the new oral anticoagulant apixaban.The new oral anticoagulants: results of clinical trials and practical applications.
P2860
Q28071543-7D5827B3-7C2C-4AD6-ABC3-48A36DE026B5Q33565534-680B91D6-1248-44DA-8DFF-25CD0025CD02Q33617298-D5EA1D2F-1ADC-4BAD-8C83-F817D8D1F494Q33977604-CD0B37BE-CE3A-44BF-AFA9-07A3FB9A8693Q34004770-FC69C557-5705-46F6-B1BF-1F29869A6C6DQ36244709-C23E4F5F-19FF-4FFF-A2AE-D97A872A5AEFQ36645135-E358B6C8-51BB-4B8B-B905-368C978CD85CQ37020922-4E6EC92D-97DA-4862-A14F-809E313EFFDFQ37593158-C20F7BB2-D1B7-46DF-BA86-D87DC8BA6C37Q37681956-3FBD3D2B-61FB-4C5A-A5BF-F5360FF1BFD8Q37990454-12FDA08E-66B7-410C-9C40-FC352FBEBD64Q38021981-FD9F5676-AA64-4D4F-9913-B0EFE0D6711DQ38028855-DB2AF327-CB51-4B93-816F-70023F6BBEB5Q38099775-9B87563D-5A09-4D40-BC6A-033C05DAF8F8Q38107177-B4D9247E-B755-4DD7-A092-37A9EF56B395Q38123237-D0BC6DD3-E279-40D1-ABCD-63A30DD2964CQ38710143-457A3718-2D3E-4210-86F7-A1F171647B2CQ40749422-F6557A9F-2448-44E6-A2EA-5DA945215D36Q45422418-40896988-C323-4928-9A6E-C5358A1D3B1A
P2860
New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
New oral anticoagulants should ...... ents with atrial fibrillation.
@ast
New oral anticoagulants should ...... ents with atrial fibrillation.
@en
New oral anticoagulants should ...... ents with atrial fibrillation.
@nl
type
label
New oral anticoagulants should ...... ents with atrial fibrillation.
@ast
New oral anticoagulants should ...... ents with atrial fibrillation.
@en
New oral anticoagulants should ...... ents with atrial fibrillation.
@nl
prefLabel
New oral anticoagulants should ...... ents with atrial fibrillation.
@ast
New oral anticoagulants should ...... ents with atrial fibrillation.
@en
New oral anticoagulants should ...... ents with atrial fibrillation.
@nl
P1433
P1476
New oral anticoagulants should ...... ents with atrial fibrillation.
@en
P2093
Jack Ansell
P304
165-70; discussion 170
P356
10.1161/CIRCULATIONAHA.111.031153
P407
P577
2012-01-01T00:00:00Z